Dorota Lubgan

5PUBLICATIONS
22CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)NanophotonicsRadiation therapyMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Aug 13, 2025
Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Rainer Fietkau, Michael Ghadimi, Robert Grützmann

|Feb 26, 2025
Pt-Au Nanoparticles in Combination with Near-Infrared-Based Hyperthermia Increase the Temperature and Impact on the Viability and Immune Phenotype of Human Hepatocellular Carcinoma Cells.

Marzena Szwed, Tina Jost, Emilia Majka

|Jul 13, 2021
12 × 6 Gy stereotactic radiotherapy for lung tumors. Is there a difference in response between lung metastases and primary bronchial carcinoma?

Dorota Lubgan, Sabine Semrau, Ulrike Lambrecht

|Sep 03, 2020
Targeted Natural Killer Cell-Based Adoptive Immunotherapy for the Treatment of Patients with NSCLC after Radiochemotherapy: A Randomized Phase II Clinical Trial.

Gabriele Multhoff, Sophie Seier, Stefan Stangl

|Jul 02, 2017
Stereotactic radiotherapy as primary definitive or postoperative treatment of intracranial meningioma of WHO grade II and III leads to better disease control than stereotactic radiotherapy of recurrent meningioma.

Dorota Lubgan, Sandra Rutzner, Ulrike Lambrecht

Pageof 1

Frequent Collaborators

2 joint publications

Matthias Hautmann

2 joint publications

Rainer Fietkau

1 joint publications

Maxim Shevtsov

1 joint publications

A Graham Pockley